Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline.
Where this comes from
- Record sourced from PubMed, PMID 25088811.
- Also identified by DOI 10.1038/ncomms5544 and PMC identifier 4538795.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Streptococcus agalactiae (Group B Streptococcus, GBS) is a commensal of the digestive and genitourinary tracts of humans that emerged as the leading cause of bacterial neonatal infections in Europe and North America during the 1960s. Due to the lack of epidemiological and genomic data, the reasons for this emergence are unknown. Here we show by comparative genome analysis and phylogenetic reconstruction of 229 isolates that the rise of human GBS infections corresponds to the selection and worldwide dissemination of only a few clones. The parallel expansion of the clones is preceded by the insertion of integrative and conjugative elements conferring tetracycline resistance (TcR). Thus, we propose that the use of tetracycline from 1948 onwards led in humans to the complete replacement of a diverse GBS population by only few TcR clones particularly well adapted to their host, causing the observed emergence of GBS diseases in neonates.
Medical subject headings
- Anti-Bacterial Agents
- Genes, Bacterial
- Genome, Bacterial
- Streptococcal Infections
- Streptococcus agalactiae
- Tetracycline
- Tetracycline Resistance